This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Achillion Reiterates HCV Pipeline Priorities And Reports Third Quarter And Nine Month 2013 Financial Results

In addition, any forward-looking statement in this press release represents our views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. We disclaim any duty to update any forward-looking statement, except as required by applicable law.

Statements of Operations
(Unaudited, in thousands, except per share amounts)
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
  2013 2012 2013 2012
Revenue  $ --   $ --   $ --   $ 2,489
Operating expenses:        
 Research and development  11,342  12,641  36,629  30,562
 General and administrative   2,734  2,647  9,353  7,965
 Total operating expenses  14,076  15,288  45,982  38,527
Loss from operations  (14,076)  (15,288)  (45,982)  (36,038)
Other income (expense):        
 Interest income  166  49  429  168
 Interest expense  (9)  (16)  (44)  (53)
Net loss   $ (13,919)  $ (15,255)  $ (45,597)  $ (35,923)
Net loss per share - basic and diluted   $ (0.14)  $ (0.20)  $ (0.49)  $ (0.50)
Weighted average shares outstanding - basic and diluted  96,648  74,647  93,066  72,099
Balance Sheets    
(Unaudited, in thousands)    
   September 30,   December 31,     
  2013 2011    
Cash, cash equivalents, marketable securities and interest receivable  $ 173,068  $ 77,659    
Working capital  130,395  58,731    
Total assets  176,061  81,530    
Long-term liabilities  110  347    
Total liabilities  11,648  9,483    
Total stockholders' equity  164,413  72,047    
CONTACT: Company Contact:
         Glenn Schulman
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         Carol Ready
         Ogilvy PR
         Tel. (212)880-5211
         Mary Kay Fenton
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         Seth Lewis
         The Trout Group, LLC
         Tel. (646) 378-2952

Achillion Pharmaceuticals logo

4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs